Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    873 result(s) found for: Anemia. Displaying page 11 of 44.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2004-004180-30 Sponsor Protocol Number: ECPSSFA1 Start Date*: 2005-04-04
    Sponsor Name:Hospital Clínic de Barcelona
    Full Title: Ensayo clínico multicéntrico, fase IV, abierto y aleatorizado para evaluar la eficacia de proteinsuccinilato de hierro, frente a sulfato ferroso sesquihidratado, en el tratamiento de la anemia en m...
    Medical condition: Anemia de nueva aparición en pacientes embarazadas
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023038-22 Sponsor Protocol Number: FEV-POST/ESP10 Start Date*: 2011-03-16
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Eficacia del hierro intravenoso carboximaltosa para la mejoría de la anemia postoperatoria en pacientes de prótesis de rodilla
    Medical condition: Anemia postoperatoria en pacientes de protesis de rodilla.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003821-70 Sponsor Protocol Number: 1VIT18045 Start Date*: Information not available in EudraCT
    Sponsor Name:American Regent, Inc.
    Full Title: Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044
    Medical condition: Iron Deficiency Anemia (IDA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000174-19 Sponsor Protocol Number: 9345 Start Date*: 2015-01-27
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Re...
    Medical condition: Moderate Aplastic Anemia (MAA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002601-22 Sponsor Protocol Number: ACE-011-MDS-001 Start Date*: 2013-01-02
    Sponsor Name:Celgene Corporation
    Full Title: AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES OR ...
    Medical condition: Anemia and low or intermediate-1 risk myelodysplastic syndromes, or non-proliferative chronic myelomonocytic leukemia (CMML).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054350 Chronic myelomonocytic leukemia LLT
    14.1 100000004851 10002272 Anemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010904-27 Sponsor Protocol Number: MK-2578-003 Start Date*: 2009-09-07
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease...
    Medical condition: Anemia in patient with Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009120 Chronic renal failure anaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000140-85 Sponsor Protocol Number: XM01-04 Start Date*: 2005-07-05
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, rand...
    Medical condition: treatment of anaemia in chronic renal failure patients not yet receiving dialysis
    Disease: Version SOC Term Classification Code Term Level
    8.0 10054353 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-021355-85 Sponsor Protocol Number: PI10 Start Date*: 2010-10-19
    Sponsor Name:CHU AMIENS
    Full Title: Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés r...
    Medical condition: Anémie symptomatique chez le patient transplanté rénal
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054353 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000983-29 Sponsor Protocol Number: MA 17502 Start Date*: 2005-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Effectiveness of a once weekly subcutaneous epoetin beta treatment in hemodialysis patients.
    Medical condition: Renal anemia in hemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058116
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003381-18 Sponsor Protocol Number: ML21362 Start Date*: 2007-08-31
    Sponsor Name:ROCHE
    Full Title: Etude multicentrique française, ouverte, non-comparative, évaluant la tolérance clinique et biologique de l’utilisation de l'epoetin beta (NeoRecormon®) chez des patients présentant une anémie au c...
    Medical condition: Anémie au cours de l'hépatite chronique C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055208 Hemolytic anemia drug-induced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000678-30 Sponsor Protocol Number: PRO-RENAL-REG-056 Start Date*: 2004-11-22
    Sponsor Name:Baxter Healthcare S.A.
    Full Title: An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation.
    Medical condition: Anaemia in End Stage Renal Disease (ESRD) hemodialyzed Patients
    Disease: Version SOC Term Classification Code Term Level
    7.0 10009120 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-000144-87 Sponsor Protocol Number: XM01-08 Start Date*: 2005-12-23
    Sponsor Name:BioGeneriX AG
    Full Title: Long-term efficacy and safety of subcutaneous administration of XM01 in chronic renal failure patients and comparison of once-weekly with three-times weekly administration of XM01 - A multinational...
    Medical condition: Treatment of anaemia in chronic renal failure patients
    Disease: Version SOC Term Classification Code Term Level
    8.0 10054353 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000676-13 Sponsor Protocol Number: PRO-RENAL-REG-055 Start Date*: 2004-11-19
    Sponsor Name:Baxter Healthcare S.A.
    Full Title: An Evaluation of the Efficacy of Epo-Omega in The Treatment of Anaemia in Chronic Kidney Disease (CKD) Patients When Administered by Once Weekly Subcutaneous Injection: A Dose Dependency Evaluation.
    Medical condition: Anaemia in pre-dialysis Chronic Kidney Disease (CKD) Patients
    Disease: Version SOC Term Classification Code Term Level
    7.0 10009120 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021576-28 Sponsor Protocol Number: DFG Fr 1455/6-1 Start Date*: 2011-06-21
    Sponsor Name:Universitätsklinikum Tuebingen
    Full Title: Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial
    Medical condition: extreme prematurity anemia of prematurity neurodevelopmental impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002307 Anemia of prematurity LLT
    12.1 10036615 Prematurity LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000951-42 Sponsor Protocol Number: 1517-CL-0610 Start Date*: 2013-12-04
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
    Medical condition: Anemia in Chronic Kidney Disease patients not on Dialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) SI (Completed) PT (Completed) AT (Completed) IE (Completed) DK (Completed) FI (Completed) LV (Completed) SE (Completed) FR (Completed) HR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001721-34 Sponsor Protocol Number: 20050197 Start Date*: Information not available in EudraCT
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Paediatric Subjects with Solid Tumours Receiving Cyclic Chemotherapy
    Medical condition: Chemotherapy-induced anemia (CIA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064469 Anemia post chemotherapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2024-000321-41 Sponsor Protocol Number: P-Monofer-PED-01 Start Date*: 2024-10-15
    Sponsor Name:Pharmacosmos A/S
    Full Title: A phase III, prospective, open-label, multi-center trial of ferric derisomaltose in children 0 to <18 years of age with iron deficiency anemia due to non-dialysis dependent chronic kidney disease o...
    Medical condition: Iron deficiency anemia due to non-dialysis dependent chronic kidney disease or iron deficiency anemia who are intolerant or unresponsive to oral iron.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-003370-40 Sponsor Protocol Number: GBT440-031 Start Date*: 2017-04-05
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10040644 Sickle cell disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000542-65 Sponsor Protocol Number: 200808 Start Date*: 2016-11-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to ...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) AT (Prematurely Ended) CZ (Completed) DE (Completed) PT (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) GR (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002039-40 Sponsor Protocol Number: CLNP023L12201 Start Date*: 2021-10-29
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders
    Medical condition: Immune thrombocytopenia (ITP) Cold agglutinin disease (CAD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10068863 Cold agglutinin disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 12:30:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA